From 2013 to 2019, Novapeutics LLC started as a biopharmaceutical company spun-out from the University of Pennsylvania situated at the Pennovation Works campus.  We are developing a menin-MLL (Mixed Leukemia Lineage Protein) inhibitor (menin-MLL inhibitor), a small molecule (iMen ~500 Dalton) that inhibits the menin and MLL interaction as an oral therapeutic for type 2 diabetes (T2D).  This is achieved by restoring the insulin producing beta cells would especially be useful for treating advanced stage T2D patients, many of whom suffer from inadequate and non-responsive beta cells in the pancreatic islet.  By regenerating beta cells would restore patients’ endogenous ability to produce normoglycemic factors, such as insulin and amylin to properly manage the blood sugar level.  Early stage T2D patients suffer from low insulin and/or may not respond effectively to insulin.

In 2019, Novapeutics LLC underwent a friendly reorganization allowing the co-founder Dr. Frank Leu to “re-imagine” Novapeutics LLC. The company was founded based on curing diabetes type 2, as it was and continue to be a rapidly growing global epidemic. For over a decade, Dr. Frank Leu has devoted his full time effort and resources on understanding the nature of this disease in order to come up with an effective therapeutic or an restorative approach.